Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
429 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Esophageal Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H2 2016', provides an overview of the Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects - The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Esophageal Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 9 Global Markets Direct Report Coverage 9 Esophageal Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Esophageal Cancer - Overview 11 Pipeline Products for Esophageal Cancer - Comparative Analysis 12 Esophageal Cancer - Therapeutics under Development by Companies 13 Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17 Esophageal Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Esophageal Cancer - Products under Development by Companies 21 Esophageal Cancer - Products under Investigation by Universities/Institutes 26 Esophageal Cancer - Companies Involved in Therapeutics Development 27 Adaptimmune Therapeutics Plc 27 Advaxis, Inc. 28 Advenchen Laboratories, LLC 29 Almac Discovery Limited 30 Amgen Inc. 31 ArQule, Inc. 32 Array BioPharma Inc. 33 Aslan Pharmaceuticals Pte. Ltd. 34 ATLAB Pharma SAS 35 Bayer AG 36 Betta Pharmaceuticals Co. Ltd. 37 Boehringer Ingelheim GmbH 38 Celgene Corporation 39 Celldex Therapeutics, Inc. 40 Cellectar Biosciences, Inc. 41 Cerulean Pharma, Inc. 42 Cyclacel Pharmaceuticals, Inc. 43 F. Hoffmann-La Roche Ltd. 44 Genmab A/S 45 GlaxoSmithKline Plc 46 Glycotope GmbH 47 Hutchison MediPharma Limited 48 Ignyta, Inc. 49 ImmunoFrontier, Inc. 50 Immunomedics, Inc. 51 Johnson & Johnson 52 Komipharm International Co., Ltd. 53 MacroGenics, Inc. 54 MaxiVAX SA 55 Mebiopharm Co., Ltd. 56 MedImmune, LLC 57 Merck & Co., Inc. 58 Mirna Therapeutics, Inc. 59 Novartis AG 60 Omeros Corporation 61 Omnitura Therapeutics Inc. 62 Oncolys BioPharma Inc 63 OncoMed Pharmaceuticals, Inc. 64 Ono Pharmaceutical Co., Ltd. 65 Pfizer Inc. 66 Proteo, Inc. 67 Puma Biotechnology, Inc. 68 Rhizen Pharmaceuticals S.A. 69 Shionogi & Co., Ltd. 70 Spectrum Pharmaceuticals, Inc. 71 Symphogen A/S 72 Taiho Pharmaceutical Co., Ltd. 73 Taiwan Liposome Company, Ltd. 74 Takara Bio Inc. 75 Transgene Biotek Limited 76 VioQuest Pharmaceuticals, Inc. 77 XuanZhu Pharma Co., Ltd. 78 Esophageal Cancer - Therapeutics Assessment 79 Assessment by Monotherapy Products 79 Assessment by Combination Products 80 Assessment by Target 81 Assessment by Mechanism of Action 86 Assessment by Route of Administration 91 Assessment by Molecule Type 93 Drug Profiles 95 (tipiracil hydrochloride + trifluridine) - Drug Profile 95 1-BB1 - Drug Profile 101 ADXS-HER2 - Drug Profile 102 afatinib dimaleate - Drug Profile 106 AL-3818 - Drug Profile 117 ALM-301 - Drug Profile 119 alpelisib - Drug Profile 120 AMG-337 - Drug Profile 123 apatinib - Drug Profile 125 atezolizumab - Drug Profile 128 ATL-101 - Drug Profile 141 binimetinib - Drug Profile 143 brontictuzumab - Drug Profile 150 CDX-1401 - Drug Profile 153 Cellular Immunotherapy for Oncology - Drug Profile 156 Cellular Immunotherapy for Oncology - Drug Profile 157 Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 158 Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile 159 cetuximab biobetter - Drug Profile 160 CGX-1321 - Drug Profile 162 CRLX-101 - Drug Profile 163 CYC-140 - Drug Profile 174 DKN-01 - Drug Profile 175 donafenib - Drug Profile 177 durvalumab - Drug Profile 178 elgemtumab - Drug Profile 188 erdafitinib - Drug Profile 190 futuximab - Drug Profile 192 ganetespib - Drug Profile 195 gedatolisib - Drug Profile 207 GSK-2256098 - Drug Profile 209 GSK-3377794 - Drug Profile 211 HMPL-309 - Drug Profile 217 I131-CLR1404 - Drug Profile 218 icotinib hydrochloride - Drug Profile 222 IMF-001 - Drug Profile 224 JS-001 - Drug Profile 225 KML-001 - Drug Profile 226 margetuximab - Drug Profile 228 MBP-426 - Drug Profile 231 miR-215 - Drug Profile 233 MMD-37K - Drug Profile 234 Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile 235 MVXONCO-1 - Drug Profile 236 neratinib - Drug Profile 237 nimotuzumab - Drug Profile 251 nintedanib - Drug Profile 255 nivolumab - Drug Profile 265 OBP-301 - Drug Profile 295 OMN-54 - Drug Profile 297 paclitaxel albumin bound - Drug Profile 299 panitumumab - Drug Profile 307 pasireotide ER - Drug Profile 312 PCA-062 - Drug Profile 315 pembrolizumab - Drug Profile 316 pralatrexate - Drug Profile 348 RXDX-106 - Drug Profile 353 S-222611 - Drug Profile 355 S-588410 - Drug Profile 356 sacituzumab - Drug Profile 358 SDS-eCAR - Drug Profile 366 sirotinib - Drug Profile 367 Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 368 Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 369 SMYD-2BAY02 - Drug Profile 370 TBI-1201 - Drug Profile 371 TBL-0805E - Drug Profile 373 TGR-1202 - Drug Profile 374 tiprelestat - Drug Profile 381 tisotumab vedotin - Drug Profile 385 tivantinib - Drug Profile 387 TLC-388 - Drug Profile 393 triciribine phosphate - Drug Profile 395 Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile 399 varlitinib - Drug Profile 400 YQ-23 - Drug Profile 403 Esophageal Cancer - Dormant Projects 404 Esophageal Cancer - Discontinued Products 409 Esophageal Cancer - Product Development Milestones 410 Featured News & Press Releases 410 Appendix 423 Methodology 423 Coverage 423 Secondary Research 423 Primary Research 423 Expert Panel Validation 423 Contact Us 423 Disclaimer 424
List of Tables
Number of Products under Development for Esophageal Cancer, H2 2016 16 Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016 17 Number of Products under Development by Companies, H2 2016 18 Number of Products under Development by Companies, H2 2016 (Contd..1) 19 Number of Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Development by Companies, H2 2016 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H2 2016 22 Comparative Analysis by Late Stage Development, H2 2016 23 Comparative Analysis by Clinical Stage Development, H2 2016 24 Comparative Analysis by Early Stage Development, H2 2016 25 Products under Development by Companies, H2 2016 26 Products under Development by Companies, H2 2016 (Contd..1) 27 Products under Development by Companies, H2 2016 (Contd..2) 28 Products under Development by Companies, H2 2016 (Contd..3) 29 Products under Development by Companies, H2 2016 (Contd..4) 30 Products under Investigation by Universities/Institutes, H2 2016 31 Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 32 Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2016 33 Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 34 Esophageal Cancer - Pipeline by Almac Discovery Limited, H2 2016 35 Esophageal Cancer - Pipeline by Amgen Inc., H2 2016 36 Esophageal Cancer - Pipeline by ArQule, Inc., H2 2016 37 Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2016 38 Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016 39 Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 40 Esophageal Cancer - Pipeline by Bayer AG, H2 2016 41 Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 42 Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 43 Esophageal Cancer - Pipeline by Celgene Corporation, H2 2016 44 Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 45 Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016 46 Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 47 Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 48 Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 49 Esophageal Cancer - Pipeline by Genmab A/S, H2 2016 50 Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 51 Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2016 52 Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 53 Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2016 54 Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2016 55 Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2016 56 Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2016 57 Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H2 2016 58 Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2016 59 Esophageal Cancer - Pipeline by MaxiVAX SA, H2 2016 60 Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016 61 Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2016 62 Esophageal Cancer - Pipeline by Merck & Co., Inc., H2 2016 63 Esophageal Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016 64 Esophageal Cancer - Pipeline by Novartis AG, H2 2016 65 Esophageal Cancer - Pipeline by Omeros Corporation, H2 2016 66 Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016 67 Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016 68 Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 69 Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 70 Esophageal Cancer - Pipeline by Pfizer Inc., H2 2016 71 Esophageal Cancer - Pipeline by Proteo, Inc., H2 2016 72 Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016 73 Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 74 Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016 75 Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 76 Esophageal Cancer - Pipeline by Symphogen A/S, H2 2016 77 Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 78 Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 79 Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2016 80 Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2016 81 Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 82 Esophageal Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 83 Assessment by Monotherapy Products, H2 2016 84 Assessment by Combination Products, H2 2016 85 Number of Products by Stage and Target, H2 2016 87 Number of Products by Stage and Mechanism of Action, H2 2016 92 Number of Products by Stage and Route of Administration, H2 2016 97 Number of Products by Stage and Molecule Type, H2 2016 99 Esophageal Cancer - Dormant Projects, H2 2016 409 Esophageal Cancer - Dormant Projects (Contd..1), H2 2016 410 Esophageal Cancer - Dormant Projects (Contd..2), H2 2016 411 Esophageal Cancer - Dormant Projects (Contd..3), H2 2016 412 Esophageal Cancer - Dormant Projects (Contd..4), H2 2016 413 Esophageal Cancer - Discontinued Products, H2 2016 414
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
